Distal colitis refractory to standard therapy is a complex and challen
ging problem. Physiological differences between the right and left col
on may be exploited for maximum therapeutic benefit, Over-reliance on
oral therapy should be seen as one of the reasons for treatment failur
e and delivery systems should target therapy to the distribution of th
e disease in doses proven to be therapeutically beneficial, The clinic
ian should also be cognizant of potential adverse effects of standard
therapies, particularly colitis due to mesalazine, which may mimic wor
sening disease. Numerous endogenous and exogenous factors that may exa
cerbate the underlying inflammatory bowel disease are discussed, This
review explores the potential mechanisms why distal colitis may be ref
ractory to therapy and addresses newer therapies that, while still in
the investigatory stages, offer hope for a widening armamentarium of t
herapeutic modalities.